Quick navigation menu :

  1. Go to content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the help menu
  5. Go to the modules
  6. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. Our Websites |
     
  3. Global Business Websites |
     
  4. Contact Us |
  5. Site map |
  6. Help
  1. Font size

    Reduce font size Increase font size  
 
 

Your Health

Contact Us

Sanofi in Syria,
Damascus office:

Mezzeh – Opposite Jalaa’ Gymnasium
Damascus – Syria
P.O. Box 2861
Tel : +963 11 612 0766
Fax : +963 11 611 4914

Content :

Central Nervous System

Sanofi therapies for central nervous system disorders:

 

A cluster of complex diseases

Since the human neuronal system is extremely complex most of the disease affecting the central nervous system (CNS) do not receive optimal treatment with currently available therapies.

Some of these conditions are:

  • Alzheimer’s disease: a neurodegenerative pathology which progressively impairs cognitive ability, and brings about behavioural disorders and functional deterioration leading to dementia,

  • Multiple Sclerosis (MS): characterized by destruction of the myelin, which covers and protects the nerves of the central nervous system,

  • Schizophrenia: generally a chronic disease marked by delirium, hallucinations or introspection and inability to act,

  • And also Insomnia, Anxiety, Parkinson’s disease

Epilepsy

Epilepsy is the most common serious neurological disorder. Children under 10 and old people are particularly vulnerable.

It is characterised by repeated spontaneous seizures caused by an excessive discharge of neurons in the brain. Seizures themselves can lead to injury, and the condition often results in a profound loss of self-confidence. There is also a significant mortality associated with epilepsy.

However, with good counselling and treatment (including new techniques of functional cerebral imaging as well as drugs that reduce the incidence of seizures), the vast majority of patients can live normal productive and fulfilling lives. Sanofi manufactures a broad spectrum anti-epileptic drug that has been available for over 30 years.

These are major public health issues

Approximately 22 million patients suffer from various forms of dementia, two thirds of which are related to Alzheimer’s. Prevalence of this disease could double within the next 25years. The WHO (World Health Organization) estimates the number of people suffering from multiple sclerosis worldwide at 2.5 million. As for schizophrenia, 1% of the world’s population may be at risk.

Update: April 01, 2006